| 靶点: |
IC50: 0.079 µM (EphB3) |
| 体内研究: |
LDN-211904(0.1 mg/kg;腹腔注射;每周三次;持续 21 天)oxalate 可抑制并克服体内 Cetuximab 耐药性。 |
| 参考文献: |
1. Qiao L, et al. Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6122-6. 2. Park SH, et al. Sonic hedgehog pathway activation is associated with cetuximab resistance and EPHB3 receptor induction in colorectal cancer. Theranostics. 2019 Apr 12;9(8):2235-2251. |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.248 ml |
11.239 ml |
22.479 ml |
| 5 mM |
0.45 ml |
2.248 ml |
4.496 ml |
| 10 mM |
0.225 ml |
1.124 ml |
2.248 ml |
| 50 mM |
0.045 ml |
0.225 ml |
0.45 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |